Skip to main content
main-content

01.12.2014 | Research | Ausgabe 1/2014 Open Access

Journal of Experimental & Clinical Cancer Research 1/2014

miR-302b is a potential molecular marker of esophageal squamous cell carcinoma and functions as a tumor suppressor by targeting ErbB4

Zeitschrift:
Journal of Experimental & Clinical Cancer Research > Ausgabe 1/2014
Autoren:
Mingxin Zhang, Qi Yang, Lingmin Zhang, Suna Zhou, Wenguang Ye, Qinglin Yao, Zongfang Li, Cheng Huang, Qinsheng Wen, Jingjie Wang
Wichtige Hinweise

Electronic supplementary material

The online version of this article (doi:10.​1186/​1756-9966-33-10) contains supplementary material, which is available to authorized users.
Mingxin Zhang, Qi Yang, Lingmin Zhang contributed equally to this work.

Competing interests

The authors declare that they have no competing interests.

Authors’ contributions

MZ, LZ and QY constructed the manuscript. MZ, LZ and QY were responsible for clinical data and evaluated clinical data; formed analysis of relation between clinical data and survival data. QY, SZ and WY carried out intro experiments. ZL, CH, QW, and JW reviewed the manuscript. All authors read and approval the final manuscript.

Abstract

Background

ErbB4 expression has been noted in various tumors, but its regulatory mechanism in esophageal squamous cell carcinoma (ESCC) remains unclear. The aim of this study was to investigate whether miR-302b regulates the expression of ErbB4 at the post-transcriptional level and to determine its expression, significance, and function in ESCC.

Methods

We used real-time reverse transcriptase-polymerase chain reaction to quantify the expression of miR-302b in 50 ESCC tissues and analyzed its relationship with clinicopathological factors and survival. Then, we investigated the post-transcriptional regulation of ErbB4 expression using immunoblot analysis and luciferase reporter assays. Finally, the effects of miR-302b on proliferation, apoptosis, and invasion of ESCC cells was detected using MTT, flow cytometric analysis, and transwell invasion assays, respectively.

Results

miR-302b was significantly down-regulated and correlated with tumor differentiation and lymph node metastasis in ESCC. Univariate and multivariate analyses indicated that low miR-302b expression might be a poor prognostic factor. Further studies demonstrated that miR-302b post-transcriptionally down-regulated the expression of ErbB4 in vitro. Moreover, miR-302b inhibited proliferation by inducing apoptosis and repressed invasion in the ESCC cell lines.

Conclusions

miR-302b is a potential molecular marker of ESCC and functions as a tumor suppressor by post-transcriptionally regulating ErbB4.
Zusatzmaterial
Authors’ original file for figure 1
13046_2013_747_MOESM1_ESM.tif
Authors’ original file for figure 2
13046_2013_747_MOESM2_ESM.tif
Authors’ original file for figure 3
13046_2013_747_MOESM3_ESM.tif
Authors’ original file for figure 4
13046_2013_747_MOESM4_ESM.tif
Literatur
Über diesen Artikel

Weitere Artikel der Ausgabe 1/2014

Journal of Experimental & Clinical Cancer Research 1/2014 Zur Ausgabe

Neu im Fachgebiet Onkologie

Mail Icon II Newsletter

Bestellen Sie unseren kostenlosen Newsletter Update Onkologie und bleiben Sie gut informiert – ganz bequem per eMail.

Bildnachweise